Get the Stockscreener App
2.08
0.95%
-0.02
Proqr Therapeutics N V stock is traded at $2.08, with a volume of 139.88K.
It is down -0.95% in the last 24 hours and up +3.48% over the past month.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
See More
Previous Close:
$2.10
Open:
$2.1
24h Volume:
139.88K
Relative Volume:
0.39
Market Cap:
$218.84M
Revenue:
$7.05M
Net Income/Loss:
$-30.43M
P/E Ratio:
-5.491
EPS:
-0.3788
Net Cash Flow:
$21.84M
1W Performance:
-6.73%
1M Performance:
+3.48%
6M Performance:
-1.65%
1Y Performance:
+14.29%
1-Day Range:
$2.04
$2.1251
1-Week Range:
$2.04
$2.3408
52-Week Range:
$1.07
$4.62
Proqr Therapeutics N V Stock (PRQR) Company Profile
Compare PRQR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRQR
Proqr Therapeutics N V
|
2.08 | 221.22M | 7.05M | -30.43M | 21.84M | -0.3788 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-29-25 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-29-25 | Initiated | Evercore ISI | Outperform |
| Mar-10-25 | Upgrade | Citigroup | Neutral → Buy |
| Jan-10-25 | Initiated | Oppenheimer | Outperform |
| Oct-29-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Nov-08-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Mar-30-23 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Dec-22-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Feb-14-22 | Downgrade | Citigroup | Buy → Neutral |
| Feb-11-22 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| Feb-11-22 | Downgrade | Stifel | Buy → Hold |
| Feb-01-22 | Initiated | Raymond James | Strong Buy |
| May-03-21 | Initiated | Stifel | Buy |
| Mar-25-21 | Reiterated | Citigroup | Buy |
| Nov-03-20 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-12-19 | Reiterated | Chardan Capital Markets | Buy |
| Dec-19-18 | Initiated | RBC Capital Mkts | Outperform |
| Nov-15-18 | Initiated | Citigroup | Buy |
| Sep-19-18 | Initiated | Evercore ISI | Outperform |
| Sep-26-17 | Reiterated | JMP Securities | Mkt Outperform |
| Jun-20-16 | Initiated | Chardan Capital Markets | Neutral |
| Oct-15-14 | Initiated | Deutsche Bank | Buy |
| Oct-13-14 | Initiated | H.C. Wainwright | Buy |
View All
Proqr Therapeutics N V Stock (PRQR) Latest News
Chart overlay techniques for tracking ProQR Therapeutics N.V.Swing Trade Planning with Consistent Setup - Newser
ProQR Therapeutics N.V. stock outlook for YEARPrice Spike Prediction for Active Traders - Newser
Using economic indicators to assess ProQR Therapeutics N.V. potentialFree Low Risk Picks for Daily Trading - Newser
Is it the right time to buy ProQR Therapeutics N.V. stockWealth Building Review That Work - jammulinksnews.com
How institutional ownership impacts ProQR Therapeutics N.V. stockSafe Entry Screening with Data Backed Analysis - Newser
ProQR Therapeutics N.V. Company Revenue and Profit Trends: A Deep DiveBreakout Screener With Alert Based Timing - Newser
Analyzing ProQR Therapeutics N.V. with risk reward ratio chartsStock Entry Point Planner with Volume Spike - Newser
Monaco Asset Management SAM Raises Stock Position in ProQR Therapeutics N.V. (NASDAQ:PRQR) - MarketBeat
How volatile is ProQR Therapeutics N.V. stock compared to the marketAdvanced Screener Target Finder With High Returns - jammulinksnews.com
Statistical indicators supporting ProQR Therapeutics N.V.’s strengthTrend Confirmation Scanner with Entry Focus - Newser
Ranking ProQR Therapeutics N.V. among high performing stocks via toolsDaily Profit Watch With Forecast Confidence - Newser
Real time alert setup for ProQR Therapeutics N.V. performanceFree Risk Controlled Short Term Trade Plans - Newser
What makes ProQR Therapeutics N.V. stock price move sharplyDaily Pattern Analysis with Return Forecast - Newser
Volume spikes in ProQR Therapeutics N.V. stock – what they meanSummary of Consistent Growth Stock Picks - Newser
Is ProQR Therapeutics N.V. stock a growth or value playFree Watchlist for Smart Swing Trading - Newser
Will breakout in ProQR Therapeutics N.V. lead to full recoveryFree AI Driven Buy Alert Trade Blueprint - Newser
How ProQR Therapeutics N.V. stock performs during market volatilityEarnings Play Trade Plan With Alerts Shared - metal.it
Price momentum metrics for ProQR Therapeutics N.V. explainedHigh Return Strategy with Low Risk - Newser
What to do if you’re stuck in ProQR Therapeutics N.V.Free Trade Timing Strategy With Technical Data - Newser
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives $8.00 Consensus Price Target from Brokerages - MarketBeat
ProQR Announces Upcoming Presentation at RNA Editing Summit - GlobeNewswire
How does ProQR Therapeutics N.V. compare to its industry peersHigh-velocity gains - jammulinksnews.com
ProQR's RNA Editing Platform Shows Promise in Treating Severe Neurodevelopmental Diseases - Stock Titan
Does ProQR Therapeutics N.V. stock perform well during market downturnsCapitalize on emerging investment opportunities - jammulinksnews.com
Brokerages Set ProQR Therapeutics N.V. (NASDAQ:PRQR) Target Price at $8.00 - Defense World
What institutional investors are buying ProQR Therapeutics N.V. stockBuild a portfolio that stands the test of time - jammulinksnews.com
When is ProQR Therapeutics N.V. stock expected to show significant growthUnbelievable profit margins - jammulinksnews.com
Is ProQR Therapeutics N.V. stock overvalued or undervaluedInvest smarter with daily market updates - jammulinksnews.com
Buy Signal for ProQR Therapeutics N.V. Stock Key Technical Indicators to WatchFree Investment Community - Newser
Why ProQR Therapeutics N.V. stock attracts strong analyst attentionBest Stocks for Capital Safety - Newser
Is ProQR Therapeutics N.V. a good long term investmentFree Popular Stock Recommendations - PrintWeekIndia
ProQR Therapeutics N.V. Stock Analysis and ForecastMarket-leading growth rates - Autocar Professional
Will ProQR Therapeutics N.V. stock benefit from interest rate changesAccelerated financial growth - jammulinksnews.com
Proqr Therapeutics N V Stock (PRQR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):